Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency.
Zhang B, Gorman J, Kwon YD, Pegu A, Chao CW, Liu T, Asokan M, Bender MF, Bylund T, Damron L, Gollapudi D, Lei P, Li Y, Liu C, Louder MK, McKee K, Olia AS, Rawi R, Schön A, Wang S, Yang ES, Yang Y, Carlton K, Doria-Rose NA, Shapiro L, Seaman MS, Mascola JR, Kwong PD.
Zhang B, et al. Among authors: seaman ms.
MAbs. 2023 Jan-Dec;15(1):2165390. doi: 10.1080/19420862.2023.2165390.
MAbs. 2023.
PMID: 36729903
Free PMC article.